Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-shG9a
- Development stage
- Preclinical
- Lead developer
- University of North Carolina
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intracerebral (nucleus Accumbens)
01
Overview
AAV-shG9a is a research-stage gene-silencing tool consisting of an adeno-associated virus serotype 2 (AAV2) vector encoding a short hairpin RNA (shRNA) designed to knock down the expression of G9a (also known as EHMT2), a histone lysine dimethyltransferase. The active ingredient is the shRNA targeting the G9a gene, delivered via an AAV2 viral vector. The biological target, G9a/EHMT2, catalyzes the dimethylation of histone H3 at lysine 9 (H3K9me2), an epigenetic mark associated with gene silencing. Produced by the UNC Vector Core at the University of North Carolina, AAV-shG9a has been used in preclinical rodent models to study the role of epigenetic regulation in the nucleus accumbens (NAc) regarding stress-potentiated alcohol drinking, cocaine addiction, and anxiety-related behaviors. There is currently no known commercial developer or clinical-stage development associated with this compound.
- Other names
- AAV2-shG9aAAV-2-shG9aAAV 2-shG9aAAV-shEHMT2AAV-shEHMT-2AAV-shEHMT 2
02
Targets
EHMT2
Beyond the preview
Go deeper on AAV-shG9a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-shG9a.